

Clinical Trials and Translational Research Advisory Committee
Translational Research Strategy Subcommittee (TRSS)
Overview and Update

November 4, 2020

TRSS Mission Statement

Survey scientific horizons broadly and provide broad advice to NCI's advisory boards (BSA, CTAC, and NCAB) and NCI leadership on enhancing and broadening the overall translational research portfolio.

1. Help identify the most provocative and impactful translational research questions
2. Examine and identify the most important opportunities for application of new technologies to translational research
3. Identify translational research knowledge gaps

TRSS Working Groups

Glioblastoma

Co-Chairs:

- Walter J. Curran, Jr., M.D., F.A.C.R
- Chi V. Dang, M.D., Ph.D.

Radiation Oncology

Co-Chairs:

- Adam Dicker, M.D., Ph.D., F.A.S.T.R.O.
- Silvia Formenti, M.D.

- Roster:
<https://deainfo.nci.nih.gov/advisory/ctac/workgroup/GBM/Roster.pdf>

- Roster:
<https://deainfo.nci.nih.gov/advisory/ctac/workgroup/RO/Roster.pdf>

TRSS Working Group Timeline

- **May 8, 2019** – TRSS heard a presentation on the initial Glioblastoma Working Group recommendations
- **July 8, 2019** – TRSS accepted the Glioblastoma Working Group report for submission to CTAC
- **July 17, 2019** – CTAC approved the Glioblastoma Working Group report
 - **May 12, 2020** – BSA approved an RFA to establish the NCI Glioblastoma Therapeutics Network (GTN) to enhance support for discovery and development of glioblastoma therapies
 - **August 27, 2020** – RFA released for the GTN:
<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-047.html>
- **October 5, 2020** – TRSS accepted the Radiation Oncology Working Group report, with suggested modifications, for submission to CTAC

CTAC TRSS Meeting Summaries

Proposed Motion:

Accept the TRSS meeting summaries from May 8, 2019, July 8, 2019, and October 5, 2020.

TRSS Next Steps

- The TRSS has now completed their initial work reviewing the reports of the *ad hoc* Working Groups on Glioblastoma and Radiation Oncology
- TRSS co-chairs and NCI leadership met to discuss next steps for the Subcommittee:
 - TRSS could provide value to NCI by identifying gaps in translational research that need more attention from NCI



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol